Tendinopathy Treatment Failure: What Counts and What Comes Next

How Clinicians Define Treatment Failure in Tendinopathy

Treatment failure is not simply "the tendon still hurts." Clinicians use a combination of time on a structured program, validated patient-reported outcome scores, and objective functional tests to make that call. The most widely cited threshold is 12 weeks of consistent, progressive loading without a clinically meaningful improvement on a validated outcome scale.

The VISA-A questionnaire for Achilles tendinopathy and the VISA-P for patellar tendinopathy are the standard instruments. A change of less than 10 to 12 points on either scale over a 12-week loading program is generally treated as insufficient response in clinical practice and in published trials. A 2013 systematic review in the British Journal of Sports Medicine confirmed that VISA scores are responsive to change and correlate with functional recovery, making them reliable markers for treatment decisions. [1]

The 12-Week Rule: Where It Comes From

The 12-week figure is not arbitrary. Alfredson et al.'s landmark 1998 randomized controlled trial of eccentric calf training (N=15 per group) showed statistically significant VISA-A gains at 12 weeks compared with concentric training, and subsequent programs adopted 12 weeks as the minimum adequate trial period. [2] Stopping sooner does not give the tendon enough time to adapt to mechanical load.

Why Program Adherence Matters Before Calling Failure

A program cannot fail if it was never properly followed. Clinicians routinely ask patients to log their sessions before concluding that the conservative approach is exhausted. Research published in JAMA in 2015 showed that adherence to a supervised exercise program was the single strongest predictor of outcome in patellar tendinopathy at 12-month follow-up, with adherent patients showing a 32% greater improvement in VISA-P scores compared with non-adherent patients. [3] Documenting at least 80% session completion is a reasonable bar before labeling a case refractory.

Imaging and Structural Criteria

Imaging alone does not define failure, but it guides escalation decisions. Persistent hypoechoic changes, neovascularization on Doppler ultrasound, or intratendinous signal on MRI after 12 weeks of loading suggests a tissue that is not remodeling. A 2010 study in the British Journal of Sports Medicine (N=61) found that persistent neovascularization on color Doppler at 6 weeks was associated with a 3.2-fold higher risk of failure to respond to a 12-week eccentric program. [4]

First-Line Treatments: What Must Be Tried Before Escalation

Calling treatment failure requires that the right treatments were actually used. Conservative care for tendinopathy has a defined hierarchy, and jumping past it disqualifies the "failure" label.

Load Management and Activity Modification

The first step is reducing the provocative load while maintaining overall conditioning. Complete rest is counterproductive. Tendons require mechanical stimulus to synthesize collagen. A 2019 narrative review in the British Journal of Sports Medicine summarized that relative load reduction, not immobilization, is the appropriate first maneuver. [5]

Eccentric and Heavy Slow-Resistance Exercise

Eccentric loading remains the most studied non-surgical intervention for tendinopathy. Beyer et al.'s 2015 RCT (N=58) comparing heavy slow resistance training with eccentric training in Achilles tendinopathy found both approaches produced similar improvements in VISA-A at 12 weeks (mean change: 27 points eccentric vs. 24 points heavy slow resistance; P<0.05 vs. Baseline for both), with heavy slow resistance showing better patient satisfaction at 1-year follow-up. [6]

Isometric loading is used acutely to reduce pain before progressing to isotonic exercises. Rio et al.'s 2015 crossover trial (N=20 patellar tendinopathy) showed a single isometric bout reduced pain scores by 40% immediately post-exercise, an effect not seen with isotonic exercise. [7]

NSAIDs: Short-Term Pain Management Only

Non-steroidal anti-inflammatory drugs offer short-term symptom relief but do not change the underlying degenerative tendon pathology. The NICE guidelines on tendinopathy advise against prolonged NSAID use, noting that tendinopathy is predominantly a degenerative rather than an inflammatory process. Using NSAIDs alone for more than 4 to 6 weeks without a structured loading program does not constitute adequate conservative care and should not count toward the 12-week failure clock.

Second-Line Options When Conservative Care Fails

Once 12 weeks of proper conservative care have produced less than a 10-point VISA improvement and imaging confirms persistent tendon pathology, clinicians have several evidence-backed second-line choices.

Platelet-Rich Plasma (PRP) Injections

PRP concentrates autologous growth factors, including platelet-derived growth factor and transforming growth factor beta, to stimulate collagen synthesis. The evidence base for PRP in tendinopathy is growing but inconsistent across tendon locations.

For lateral epicondyle tendinopathy, a 2006 pilot RCT by Mishra and Pavelko (N=20) reported 93% improvement in pain scores in PRP-treated patients versus 0% in the corticosteroid group at 8-week follow-up. [8] A larger 2013 RCT in the American Journal of Sports Medicine (N=230) confirmed PRP superiority over corticosteroid at 24 weeks, with an absolute difference of 25.1 points on the DASH score. [9]

For Achilles tendinopathy, results are more mixed. De Vos et al.'s 2010 RCT published in JAMA (N=54) found no significant difference between PRP and saline injection when both groups followed an eccentric program (VISA-A improvement 21.7 points PRP vs. 20.5 points saline; P = 0.89). [10] That finding does not make PRP useless for Achilles tendinopathy but it does mean PRP should not replace structured loading; it should supplement it.

High-Volume Injection (HVI)

High-volume injection, typically 10 mL of bupivacaine plus 40 mg methylprednisolone plus 30 to 40 mL normal saline, aims to mechanically disrupt the neovascular ingrowth that accompanies chronic tendinopathy. A 2012 RCT in the British Journal of Sports Medicine (N=43) showed significantly greater VISA-A improvement at 6 weeks in the HVI group versus saline control (23 vs. 8 points; P<0.001). [11]

Sclerosing Injections

Polidocanol sclerotherapy targets neovascularization. Ohberg and Alfredson's 2002 case series (N=10) in the British Journal of Sports Medicine showed complete pain resolution in 8 of 10 Achilles tendinopathy patients who were pain-free at 6-month follow-up after polidocanol injections guided by color Doppler. [12] Subsequent controlled studies showed more modest but still clinically meaningful benefit compared with placebo.

Extracorporeal Shockwave Therapy (ESWT)

ESWT uses acoustic waves to stimulate tendon healing. A Cochrane review from 2014 (9 RCTs, N=955) found ESWT produced statistically significant pain reduction compared with placebo for calcific shoulder tendinopathy but effects were smaller and less consistent for Achilles and patellar tendinopathy. [13] ESWT is nonetheless widely used as a bridge between conservative care and injection-based treatment given its low risk profile.

Off-Label and Investigational Approaches

Some patients and clinicians turn to off-label peptides and biologics after standard second-line options have been exhausted. These carry a different risk-benefit calculus and require explicit informed consent.

BPC-157

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a human gastric protein. Animal models show accelerated tendon-to-bone healing, with a 2010 study in the Journal of Applied Physiology reporting a 30% increase in breaking strength in BPC-157-treated rat Achilles tendons at 4 weeks compared with controls. [14] No large-scale human RCTs exist. The FDA has not approved BPC-157 for any indication. It is not available as a licensed pharmaceutical, and its safety profile in humans over long periods is unknown.

The HealthRX medical team uses the following decision framework for discussing BPC-157 with patients who have failed 12+ weeks of conservative care and at least one injection-based treatment:

1. Confirm tendon integrity on imaging (no partial rupture).
2. Rule out systemic causes of tendon fragility (fluoroquinolone use, metabolic disease, inflammatory arthropathy).
3. Document written informed consent including absence of FDA approval and absence of human efficacy data.
4. Set a clear 8-week reassessment with VISA re-scoring as an objective endpoint.

This framework does not constitute an endorsement of BPC-157. It is a structure for minimizing harm when a patient elects to pursue an investigational option.

Corticosteroid Injections: A Note on Sequencing

Corticosteroid injections reduce short-term pain (4 to 6 weeks) but are associated with worse long-term outcomes at 1 year compared with watchful waiting. A landmark RCT by Coombes et al. In The Lancet (2013, N=165) found that corticosteroid injection for lateral epicondyle tendinopathy produced a 57% recurrence rate at 1 year versus 29% in the placebo group (P<0.001). [15] For this reason, most sport medicine guidelines now position corticosteroid as a short-term symptom-management tool rather than a curative treatment, and repeated corticosteroid injections should not fill the "12 weeks of conservative care" requirement.

Surgical Referral: Criteria and Timing

Surgery for tendinopathy is a last resort with variable evidence, and selecting the right patient is more important than choosing the technique.

General Criteria for Surgical Referral

Most published guidelines suggest considering surgery after:

• 6 to 12 months of failed conservative and second-line treatment
• Confirmed structural pathology on imaging (intratendinous degeneration, partial rupture)
• Functionally disabling symptoms that prevent occupational or recreational activity
• A score below 50 on VISA-A or VISA-P after two consecutive 12-week loading cycles

A 2011 systematic review in the British Journal of Sports Medicine (22 studies, N=862) found that surgical debridement for chronic Achilles tendinopathy produced good-to-excellent outcomes in approximately 75% of patients at 2-year follow-up, though no study was powered for non-inferiority against intensive conservative care. [16]

Achilles Tendinopathy Surgery

Open or endoscopic stripping of peritendinous tissue and removal of degenerate tendon tissue (Haglund's resection for insertional disease) are the main options. Return to sport averages 6 to 12 months post-operatively.

Patellar Tendinopathy Surgery

Arthroscopic debridement of the proximal patellar tendon is reserved for athletes who have failed all conservative measures. Success rates are around 70% at 2 years based on the current observational data.

Rotator Cuff and Lateral Epicondyle Tendinopathy Surgery

For the rotator cuff, surgical repair is considered when structural tear complicates pure tendinopathy. For lateral epicondyle tendinopathy (tennis elbow), open or arthroscopic release of the extensor carpi radialis brevis tendon shows 80 to 90% good outcomes in selected patients with confirmed failed conservative and injection-based management at 6 months. [17]

Monitoring Progress: Outcome Measures Every Clinician Should Track

Defining failure requires prospective tracking. Treating patients without collecting validated outcome data at baseline and at 6 and 12 weeks makes it impossible to objectively call failure or success.

VISA Scores

The Victorian Institute of Sport Assessment questionnaires are the benchmark. VISA-A for Achilles, VISA-P for patellar tendinopathy. Scores range 0 to 100, with 100 representing full function and no pain. A score below 50 at baseline identifies severe tendinopathy. A gain of fewer than 10 points over 12 weeks is the conventional failure threshold.

Pain With Activity (NRS)

The Numeric Rating Scale (0 to 10) measured during a standard load (single-leg decline squat for patellar, single-leg heel raise for Achilles) gives a quick real-world functional marker. A score above 5/10 with normal activity after 12 weeks of treatment suggests inadequate response.

Return-to-Sport and Recurrence Data

Even successful treatment carries a significant recurrence burden. A 2020 systematic review in the British Journal of Sports Medicine (N=1,234) found that up to 44% of athletes with Achilles tendinopathy experienced a recurrence within 12 months of return to sport, underscoring the need for continued load monitoring beyond the acute treatment period. [18]

Special Populations: When the Timeline Shifts

Standard 12-week failure thresholds apply to most patients, but some groups warrant earlier or later escalation.

Competitive Athletes

A professional or competitive athlete with a tournament or competitive season approaching may reasonably receive second-line treatment (PRP or ESWT) earlier, at 6 to 8 weeks, if VISA scores show a plateau and imaging shows persistent pathology. The British Journal of Sports Medicine 2019 consensus statement acknowledges this exception explicitly. [5]

Older Adults With Metabolic Comorbidities

Diabetes, dyslipidemia, and obesity all impair tendon healing. A 2011 study in Rheumatology (N=1,159) found that patients with type 2 diabetes had a significantly higher rate of tendon pathology on ultrasound (23.5% vs. 7.4% in controls; P<0.001) and lower rates of response to conservative loading programs. [19] For these patients, addressing the metabolic driver alongside the tendon loading program is essential, and the failure threshold may need to be extended to 16 weeks given slower tissue metabolism.

Adolescents and Young Athletes

Apophyseal conditions (Osgood-Schlatter, Sinding-Larsen-Johansson) overlap with patellar tendinopathy symptomatically but respond to different programs and typically resolve with skeletal maturation. Mislabeling these as tendinopathy treatment failures can lead to unnecessary injections. Confirm diagnosis with imaging before escalating.

A Practical Checklist Before Declaring Tendinopathy Refractory

Before any second-line intervention is ordered, a structured review of the conservative program should confirm:

• Minimum 12 weeks on a supervised or documented eccentric or heavy slow-resistance program
• Documented session adherence of at least 80%
• VISA scores collected at baseline and at 6 and 12 weeks
• Load-monitoring diary showing progressive load increase (not flat loading)
• Imaging confirming ongoing structural pathology
• Metabolic and systemic contributors reviewed and addressed
• Corticosteroid injections counted as symptom management, not as part of the 12-week failure clock
• Patient education confirmed: the patient understands tendon remodeling takes 3 to 6 months

A clinician who can check all eight items has the evidence base to confidently declare conservative treatment failure and move to second-line care. Skipping any step risks misclassifying a recoverable case as refractory.